Close Menu

Enzo

Enzo Biochem said this week that it has filed an application with New York State for approval of its first assay based on its new AmpiProbe nucleic acid detection technology.

NEW YORK (GenomeWeb News) – Enzo Biochem said today that it has filed an application with New York for approval of its first assay run on its AmpiProbe nucleic acid detection platform.

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market on Monday a 5 percent increase year over year in fiscal second-quarter revenues.

NEW YORK (GenomeWeb News) – Enzo Life Sciences this week sued Abbott, Becton Dickinson, and Hologic claiming those companies infringe Enzo's patent covering a method of modifying nucleotides for use as probes.

Enzo Biochem at the end of the month will present for the first time peer-reviewed data on detection of hepatitis C virus using its new AmpiProbe nucleic acid amplification chemistry, the company said today.

Dako, Amgen Ink CDx Deal for Undisclosed Oncologic
Dako and Amgen announced they will partner to develop a companion diagnostic for an undisclosed oncology drug that Amgen is currently advancing in clinical trials.

NEW YORK (GenomeWeb News) – The Enzo Clinical Labs division of Enzo Biochem has received approval from the New York State Department of Health to market GeneNews' ColonSentry test to residents of the state.

Enzo Biochem has re-elected Elazar Rabbani to serve as a class III director for a three-year term. Rabbani is chairman, CEO, and co-founder of Enzo.

Enzo Life Sciences has filed three separate lawsuits against Roche, Life Technologies, and Gen-Probe claiming that various nucleic acid probe-based research and diagnostics products from those companies infringe a patent owned by Enzo.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.